Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
Clinical trial NCT03943290 · TERMINATED
Trial details
- NCT number
- NCT03943290
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-10
- Primary completion
- 2020-03-11
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.